Clinical Study Results, Philanthropic Activities, Legal Orders and Updates on Share price Movements - Research Report on McKesson, CVS Caremark, Medtronic, Cardinal Health and Rite Aid

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting McKesson Corporation (NYSE: MCK), CVS Caremark Corporation (NYSE: CVS), Medtronic, Inc. (NYSE: MDT), Cardinal Health Inc (NYSE: CAH) and Rite Aid Corporation (NYSE: RAD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

McKesson Corporation Research Report

On November 14, 2013, shares of McKesson Corporation (McKesson) rose 0.99% to end the day at $159.46. Shares of McKesson went up 0.35% over the past three trading sessions, while the Dow Jones rose 0.59% over the same time period. The Full Research Report on McKesson Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a057_MCK

--

CVS Caremark Corporation Research Report

On November 13, 2013, CVS Caremark Corporation (CVS Caremark) issued a press release regarding a study conducted by researchers from the Company and from Brigham and Women's Hospital, exploring the impact of genetic testing on prescribing patterns for cardiovascular therapy. According the CVS Caremark, the study, which was published in the November 2013 issue of the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes, showed that only one in five patients who tested as poor metabolizers of the blood thinner clopidogrel had their antiplatelet therapy changed as recommended by the U. S. FDA. In addition, the study found that prescribers declined genetic testing in 25% of cases evaluated, while less than 10% of patients who were directly offered the genetic evaluation declined testing. As per the release, the researchers concluded that the prescribing patterns noted in the study likely reflect the unclear impact and physician uncertainty regarding the rapidly evolving body of evidence for pharmacogenomics. The Full Research Report on CVS Caremark Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f53e_CVS

--

Medtronic, Inc. Research Report

On November 14, 2013, Medtronic, Inc. (Medtronic) announced that a German court ordered the discontinuation, in its entirety, of a prior court ruling that prohibited Medtronic from commercially marketing or selling the CoreValve® System in Germany since August 26, 2013. According to the Company, the Higher Regional Court Karlsruhe explained that, due to the European Patent Office (EPO) preliminary opinion that the Edwards' EP2055266 Spenser patent claims are not valid, it could not assume "with sufficient likelihood" that the Spenser patent is valid. Medtronic stated that it will post the €5 million bond required by the Order as soon as possible and then resume sales in Germany. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/bc94_MDT

--

Cardinal Health Inc Research Report

On November 14, 2013 Cardinal Health Inc's (Cardinal Health) shares reached $64.51 per share, up 0.91% over the previous day's closing price. Shares of Cardinal Health have rallied 2.46% over the past three trading sessions, while the Dow Jones has risen 0.59% over the same time. The Full Research Report on Cardinal Health Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ee30_CAH

--

Rite Aid Corporation Research Report

On November 13, 2013, Rite Aid Corporation (Rite Aid) announced a $50,000 donation to the American Red Cross via The Rite Aid Foundation, to help the victims, families, communities in the Philippines affected by Typhoon Haiyan. "Our hearts go out to the people and communities affected by Typhoon Haiyan," said Ken Martindale, Rite Aid's President and Chief Operating Officer and President of The Rite Aid Foundation. "So many lives were forever changed as a result of this devastating tropical storm. The Rite Aid Foundation is proud to partner with the American Red Cross as their team provides critical services and support for the people of the Philippines in their time of need." Roger Lowe, Senior Vice President - Communications at the American Red Cross added, "The generous support of The Rite Aid Foundation will help the Red Cross support people affected by Typhoon Haiyan, both in the emergency response and as people and communities work to rebuild their lives." The Full Research Report on Rite Aid Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f64e_RAD

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED